|
Nov 1
|
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
|
|
Nov 1
|
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
|
|
Nov 1
|
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
|
|
Oct 31
|
Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
|
|
Oct 31
|
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
|
|
Oct 31
|
Teva Statement on European Commission Decision; Company to Appeal
|
|
Oct 1
|
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
|
|
Oct 1
|
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
|
|
Sep 30
|
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
|
|
Sep 30
|
Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...
|
|
Aug 5
|
Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Aug 1
|
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
|
|
Jul 31
|
Teva Pharma, With A 67% Gain This Year, Flirts With A Breakout On Beat-And-Raise Report
|
|
Jul 29
|
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
|
|
Jul 29
|
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
|
|
Jul 25
|
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
|
|
Jul 2
|
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
|
|
Jul 2
|
FTC investigates Teva over contested product patents
|
|
Jul 1
|
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
|
|
Jul 1
|
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity
|